Independent monitoring committee recommends halting REGN-COV2 trial

By The Science Advisory Board staff writers

November 2, 2020 -- The independent data monitoring committee of the REGN-COV2 antibody cocktail treatment trials for COVID-19 has recommended holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements.

The decision is based on a potential safety signal and an unfavorable risk/benefit profile at this time. The committee recommended further collection and data analysis of patients already enrolled. Lastly, the committee recommended continuing the outpatient trial without modification.

Regeneron Pharmaceuticals, the firm spearheading the trial, remains blinded to the data and is implementing the committee's recommendations. The firm is also informing the U.S. Food and Drug Administration (FDA), which is currently evaluating REGN-COV2 for a potential emergency use authorization (EUA) in mild-to-moderate outpatients at high risk for poor outcomes. Regeneron is also sharing the recommendation with the independent committee monitoring the Recovery trial in the U.K.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here